{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T07:02:49Z","timestamp":1768978969641,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Key Program of Zhejiang Province Natural Science Foundation of China","award":["LZ24H160001"],"award-info":[{"award-number":["LZ24H160001"]}]},{"name":"the Fundamental Research Funds for the Central Universities","award":["2023QZJH54"],"award-info":[{"award-number":["2023QZJH54"]}]},{"name":"4+X Clinical Research Project of Women\u2019s Hospital, School of Medicine, Zhejiang University","award":["ZDFY2022-4X202"],"award-info":[{"award-number":["ZDFY2022-4X202"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82472891"],"award-info":[{"award-number":["82472891"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-024-03562-8","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T04:01:51Z","timestamp":1729483311000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of PARP inhibitors on progression-free survival in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective analysis"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6706-1786","authenticated-orcid":false,"given":"Yumei","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2377-0775","authenticated-orcid":false,"given":"Junfen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"key":"3562_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3562_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/jnci\/djy071","volume":"111","author":"LC Peres","year":"2019","unstructured":"Peres LC, Cushing-Haugen KL, Kobel M, Harris HR, Berchuck A, Rossing MA, et al. Invasive epithelial ovarian cancer survival by histotype and disease stage. J Natl Cancer Inst. 2019;111:60\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"3562_CR3","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","volume":"35","author":"JA Ledermann","year":"2024","unstructured":"Ledermann JA, Matias-Guiu X, Amant F, Concin N, Davidson B, Fotopoulou C, et al. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Ann Oncol. 2024;35:248\u201366.","journal-title":"Ann Oncol"},{"key":"3562_CR4","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s11523-023-00970-w","volume":"18","author":"DM O\u2019Malley","year":"2023","unstructured":"O\u2019Malley DM, Krivak TC, Kabil N, Munley J, Moore KN. PARP inhibitors in ovarian cancer: a review. Target Oncol. 2023;18:471\u2013503.","journal-title":"Target Oncol"},{"key":"3562_CR5","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1200\/JCO.2014.58.8848","volume":"33","author":"CL Scott","year":"2015","unstructured":"Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol. 2015;33:1397\u2013406.","journal-title":"J Clin Oncol"},{"key":"3562_CR6","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274\u201384.","journal-title":"Lancet Oncol"},{"key":"3562_CR7","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ygyno.2021.12.025","volume":"164","author":"A Poveda","year":"2022","unstructured":"Poveda A, Lheureux S, Colombo N, Cibula D, Lindemann K, Weberpals J, et al. Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1\/BRCA2 mutation: OPINION primary analysis. Gynecol Oncol. 2022;164:498\u2013504.","journal-title":"Gynecol Oncol"},{"key":"3562_CR8","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154\u201364.","journal-title":"N Engl J Med"},{"key":"3562_CR9","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.annonc.2020.12.018","volume":"32","author":"XH Wu","year":"2021","unstructured":"Wu XH, Zhu JQ, Yin RT, Yang JX, Liu JH, Wang J, et al. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial(\u2606). Ann Oncol. 2021;32:512\u201321.","journal-title":"Ann Oncol"},{"key":"3562_CR10","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","volume":"34","author":"A Gonzalez-Martin","year":"2023","unstructured":"Gonzalez-Martin A, Harter P, Leary A, Lorusso D, Miller RE, Pothuri B, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:833\u201348.","journal-title":"Ann Oncol"},{"key":"3562_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205\u201316.","journal-title":"J Natl Cancer Inst"},{"key":"3562_CR12","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","volume":"19","author":"NJ Curtin","year":"2020","unstructured":"Curtin NJ, Szabo C. Poly(ADP-ribose) polymerase inhibition: past, present and future. Nat Rev Drug Discov. 2020;19:711\u201336.","journal-title":"Nat Rev Drug Discov"},{"key":"3562_CR13","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1158\/1541-7786.MCR-11-0477","volume":"10","author":"PS Kedar","year":"2012","unstructured":"Kedar PS, Stefanick DF, Horton JK, Wilson SH. Increased PARP-1 association with DNA in alkylation damaged, PARP-inhibited mouse fibroblasts. Mol Cancer Res. 2012;10:360\u20138.","journal-title":"Mol Cancer Res"},{"key":"3562_CR14","doi-asserted-by":"publisher","first-page":"362ps17","DOI":"10.1126\/scitranslmed.aaf9246","volume":"8","author":"Y Pommier","year":"2016","unstructured":"Pommier Y, O\u2019Connor MJ, de Bono J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci Transl Med. 2016;8:362ps17.","journal-title":"Sci Transl Med"},{"key":"3562_CR15","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","volume":"22","author":"A Poveda","year":"2021","unstructured":"Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22:620\u201331.","journal-title":"Lancet Oncol"},{"issue":"suppl7","key":"3562_CR16","doi-asserted-by":"publisher","first-page":"S790","DOI":"10.1016\/j.annonc.2022.07.659","volume":"33","author":"AM Velasco","year":"2022","unstructured":"Velasco AM, Lheureux S, Colombo N, Cibula D, Elstrand M, Weberpals J, et al. Maintenance olaparib monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) without a germline BRCA1\/BRCA2 mutation (non-gBRCAm): final overall survival (OS) results from the OPINION trial. Ann Oncol. 2022;33(suppl7):S790.","journal-title":"Ann Oncol"},{"key":"3562_CR17","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1200\/JCO.18.02238","volume":"37","author":"JM Del Campo","year":"2019","unstructured":"Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, et al. Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16\/NOVA trial. J Clin Oncol. 2019;37:2968\u201373.","journal-title":"J Clin Oncol"},{"key":"3562_CR18","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.ygyno.2018.12.009","volume":"152","author":"M Fabbro","year":"2019","unstructured":"Fabbro M, Moore KN, Dorum A, Tinker AV, Mahner S, Bover I, et al. Efficacy and safety of niraparib as maintenance treatment in older patients (>\/= 70 years) with recurrent ovarian cancer: results from the ENGOT-OV16\/NOVA trial. Gynecol Oncol. 2019;152:560\u20137.","journal-title":"Gynecol Oncol"},{"key":"3562_CR19","first-page":"A286","volume":"34","author":"X Wu","year":"2024","unstructured":"Wu X, Zhu J, Yin R, Yang J, Liu J, Wang J, et al. 34\u2005Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 trial. Int J Gynecologic Cancer. 2024;34:A286.","journal-title":"Int J Gynecologic Cancer"},{"key":"3562_CR20","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41586-023-06548-w","volume":"623","author":"X Huang","year":"2023","unstructured":"Huang X, Henck J, Qiu C, Sreenivasan VKA, Balachandran S, Amarie OV, et al. Single-cell, whole-embryo phenotyping of mammalian developmental disorders. Nature. 2023;623:772\u201381.","journal-title":"Nature"},{"key":"3562_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40364-015-0033-4","volume":"3","author":"AM Marquard","year":"2015","unstructured":"Marquard AM, Eklund AC, Joshi T, Krzystanek M, Favero F, Wang ZC, et al. Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark Res. 2015;3:9.","journal-title":"Biomark Res"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-024-03562-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-024-03562-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-024-03562-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T16:04:03Z","timestamp":1729526643000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-024-03562-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3562"],"URL":"https:\/\/doi.org\/10.1186\/s12957-024-03562-8","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]},"assertion":[{"value":"10 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved (PRO2022-2574) by the Human Research Ethics Committee of the Women\u2019s Hospital, Zhejiang University School of Medicine, which waived the informed consent requirement due to the retrospective design of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We confirm that the manuscript has been read and approved by all named authors, and that there are no other persons who satisfied the criteria for authorship but are not listed. We also confirm that the order of the authors listed in the manuscript has been approved by all of us.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"276"}}